Mode
Text Size
Log in / Sign up
N/A Completed N=24

Special Investigation of Kaletra in Pregnant Women

Source: ClinicalTrials.gov NCT01076985 ↗
Enrolled (actual)
24
Serious AEs
13.3%
Results posted
Jan 2012
Primary outcomePrimary: Number of Patients With Adverse Drug Reactions (ADRs) — 2; 5; 1; 0 participants

Summary

This non-interventional, post-marketing observational study was conducted to obtain safety data from the use of lopinavir/ritonavir (Kaletra), in clinical practice, in pregnant women and their children in Japan.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Adverse Drug Reactions (ADRs)
2; 5; 1; 0; 1; 0 —

Eligibility Criteria

Inclusion Criteria

  • All pregnant women who have received Kaletra for the treatment of HIV infection were eligible for this study

Exclusion Criteria

  • Contraindications according to the Package Insert:
  • Patients with a history of hypersensitivity to any ingredient of Kaletra
  • Patients who are receiving pimozide, cisapride, ergotamine tartrate, dihydroergotamine mesylate, ergometrine maleate, methylergometrine maleate, midazolam, triazolam, vardenafil hydrochloride hydrate, boriconazol
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01076985). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search